Hysteroscopic resection vs ultrasound-guided dilation and evacuation for treatment of cesarean scar ectopic pregnancy: a randomized clinical trial

医学 宫颈扩张术 异位妊娠 超声波 随机对照试验 怀孕 妊娠期 外科 膨胀(度量空间) 切除术 剖宫产 产科 放射科 数学 组合数学 生物 遗传学
作者
A. Di Spiezio Sardo,Brunella Zizolfi,Gabriele Saccone,Cinzia Ferrara,G. Sglavo,Maria Chiara De Angelis,Enrica Mastantuoni,Giuseppe Bifulco
出处
期刊:American Journal of Obstetrics and Gynecology [Elsevier]
卷期号:229 (4): 437.e1-437.e7 被引量:6
标识
DOI:10.1016/j.ajog.2023.04.038
摘要

Background

Cesarean scar ectopic pregnancy is a type of ectopic pregnancy in which the fertilized egg is implanted in the muscle or fibrous tissue of the scar after a previous cesarean delivery. The condition can be catastrophic if not managed on time and can lead to significant morbidity and mortality. Several approaches have been studied for the management of cesarean scar ectopic pregnancy in women who opted for termination of pregnancy with no consensus on the best treatment modality reached so far.

Objective

This study aimed to compare the success rate of hysteroscopic resection vs ultrasound-guided dilation and evacuation for the treatment of cesarean scar ectopic pregnancy.

Study Design

This was a parallel group, nonblinded, randomized clinical trial conducted at a single center in Italy. Women with singleton gestations at <8 weeks and 6 days of gestation were included in the study. Inclusion criteria were women with a cesarean scar ectopic pregnancy with positive embryonic heart activity who opted for termination of pregnancy. Patients were randomized 1:1 to receive either hysteroscopic resection (ie, intervention group) or ultrasound-guided dilation and evacuation (ie, control group). Both groups received 50 mg/m2 of methotrexate intramuscularly at the time of randomization (day 1) and another dose at day 3. A third dose of methotrexate was planned in case of persistence of positive fetal heart activity at day 5. Participants received either ultrasound-guided dilation and evacuation or hysteroscopic resection from 1 to 5 days after the last dose of methotrexate. Hysteroscopic resection was performed under spinal anesthesia using a 15 Fr bipolar mini-resectoscope. Dilation and evacuation were performed by vacuum aspiration with a Karman cannula, followed by sharp curettage, if necessary, under ultrasound guidance. The primary outcome was the success rate of the treatment protocol, defined as no further treatment required until the complete resolution of the cesarean scar ectopic pregnancy. Resolution of the cesarean scar ectopic pregnancy was evaluated based on decline of beta-hCG and the absence of residual gestational material in the endometrial cavity. Treatment failure was defined as the necessity for further treatment required until the complete resolution of the cesarean scar ectopic pregnancy. A sample size calculation indicated that 54 participants were required to test the hypothesis

Results

A total of 54 women were enrolled and randomized. Number of previous cesarean deliveries ranged from 1 to 3. Overall, 10 women received a third dose of methotrexate with 7 of 27 (25.9%) participants in the hysteroscopic resection group and 3 of 27 (11.1%) in the dilation and evacuation group. The success rate was 100% (27/27) in the hysteroscopic resection group and 81.5% (22/27) in the dilation and evacuation group (relative risk, 1.22; 95% confidence interval, 1.01–1.48). Additional procedures were required in 5 cases of the control group, namely 3 hysterectomies, 1 laparotomic uterine segmental resection, and 1 hysteroscopic resection. The length of stay in the hospital was 9.0±2.9 days in the intervention group and 10.0±3.5 days in the control group (mean difference, −1.00 days; 95% confidence interval, −2.71 to 0.71). No cases of admission to intensive care unit or maternal death were reported.

Conclusion

Hysteroscopic resection was associated with an increased success rate in the treatment of cesarean scar ectopic pregnancy when compared with ultrasound-guided dilation and evacuation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
adazbd发布了新的文献求助10
刚刚
Jenny应助木头人采纳,获得10
刚刚
ATAYA完成签到,获得积分10
1秒前
1秒前
畏寒的北发布了新的文献求助10
1秒前
1秒前
2秒前
地下室没有鬼完成签到 ,获得积分10
2秒前
whh123完成签到 ,获得积分10
2秒前
天天快乐应助空禅yew采纳,获得10
3秒前
在水一方应助开心采纳,获得10
4秒前
Akim应助王w采纳,获得10
4秒前
towerman发布了新的文献求助10
4秒前
畅快平蓝完成签到,获得积分10
4秒前
大棒槌发布了新的文献求助10
5秒前
5秒前
Ann完成签到,获得积分10
5秒前
今今发布了新的文献求助10
6秒前
123123完成签到 ,获得积分10
6秒前
SciGPT应助伊酒采纳,获得10
7秒前
何糖发布了新的文献求助10
8秒前
ding应助SEV采纳,获得10
8秒前
田様应助csq采纳,获得10
8秒前
dafwfwaf发布了新的文献求助10
8秒前
8秒前
景别完成签到,获得积分10
9秒前
彭于晏应助zhappy采纳,获得20
9秒前
10秒前
xg发布了新的文献求助10
10秒前
11秒前
Tophet完成签到,获得积分10
11秒前
12秒前
12秒前
12秒前
FashionBoy应助落落采纳,获得10
13秒前
活力的青枫完成签到 ,获得积分10
13秒前
苏素肃发布了新的文献求助10
13秒前
14秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527961
求助须知:如何正确求助?哪些是违规求助? 3108159
关于积分的说明 9287825
捐赠科研通 2805882
什么是DOI,文献DOI怎么找? 1540070
邀请新用户注册赠送积分活动 716926
科研通“疑难数据库(出版商)”最低求助积分说明 709808